FdaApplication
NDA 217470
Identifiers
- fda_app_no: NDA217470
Properties
| Property | Value |
|---|---|
| applicant_name | INDIVIOR INC |
| application_type | NDA |
| approval_date | 2023-05-22 |
Revenue by product
OPVEE
| Period | Revenue |
|---|---|
| Q4 2025 | $0.0M |
| Q3 2025 | $8.0M |
| Q4 2024 | $0.0M |
| Q3 2024 | $15.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OPVEE | NALMEFENE HYDROCHLORIDE | EQ 2.7MG BASE/SPRAY | SPRAY;NASAL |
1 product